Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol nasal spray was well tolerated in patients with social anxiety disorder after as-needed use for up to 12 months, with no new drug-related safety findings reported. The long-term safety update is a modestly positive clinical-development signal, though no efficacy data, regulatory milestones, or financial details were provided.